Trial reportMedicine2025
A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chinese expert consensus on intranasal anticholinergics for allergic rhinitis.Asia Pacific allergy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBencycloquidium bromide (BCQB) is a novel synthesized quaternary ammonium salt compound based on the classic anticholinergic drug ipratropium bromide. This study was to compare the efficacy of BCQB and montelukast (MNT) combination therapy to that of MNT monotherapy in the treatment of moderate to severe allergic rhinitis ((M/S)AR).
methodsThis study enrolled enrolled 300 patients with (M/S)AR. The participants were randomized to receive BCQB (180 μg each time, qid) plus MNT (10 mg qn) (BCQB + MNT group) or MNT alone (10 mg qn) for 4 weeks. The visual analog scale (VAS) for rhinorrhea, sneezing, nasal congestion, itching, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) were assessed before and at the end of treatments. Adverse events were recorded in detail.
resultsFAS analysis was performed on a total of 133 and 134 patients, in the BCQB + MNT group and in MNT group, respectively. The baseline information was comparable. Both treatments significantly reduced the score of total VAS and 4 main VAS symptoms compared to baseline. However, the BCQB + MNT group exhibited significantly greater decrease in scores for rhinorrhea and nasal congestion compared to MNT alone. After 2 weeks of treatment, the BCQB + MNT group showed significantly larger decrease in the RQLQ score in terms of daily living, nonnasal and ocular symptoms, behavioral problems, nasal symptoms, and ocular symptoms compared to MNT alone. At the end of the trial, both treatments significantly reduced the total RQLQ score from baseline; however, the BCQB + MNT group showed significant decrease in scores compared to MNT alone. Mild and transient adverse events were recorded, which were similar between the 2 groups.
conclusionThe combination of BCQB and MNT had a greater overall effect, compared to MNT monotherapy in improving nasal symptoms such as nasal congestion and rhinorrhea, as well as quality of life in the treatment of (M/S)AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.